newsPsychopharmacologyPTSD
Rapid-Acting Neuroplastogen TSND-201 Shows Significant Efficacy in PTSD: Results from the Phase 2 IMPACT-1 Trial
By MedXY|Feb 20, 2026
A Phase 2 randomized clinical trial demonstrates that TSND-201, a novel neuroplastogen, significantly reduces PTSD symptoms and functional disability without intensive psychotherapy, offering a potentially rapid and durable treatment option
